News
Press Releases
Sep 28, 2023
LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity, announced tod...
Read MoreSep 14, 2023
Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer
Seasoned Expert Joins to Drive Fractyl's Pioneering Mission Forward with its Revita® and Rejuva® Programs for Type 2 Diabetes and Obesity Dr. Kieffer’s Stellar Track Record Spans Pioneering Academic Research in Diab...
Read MoreAug 30, 2023
Fractyl Health Mourns the Passing of Esteemed Board Member Brian Dovey
LEXINGTON, Mass.--(BUSINESS WIRE)-- It is with profound sadness that Fractyl Health announces the passing of Brian Dovey, a cherished member of our Board of Directors and a partner at Domain Associates, following a shor...
Read MoreAug 1, 2023
Revita+ is a pioneering partnership between the West German Diabetes and Health Centre (WDGZ) and Fractyl Health, combining Revita with telehealth behavioral modification recommendations for patients with Type 2 Diabetes...
Read MoreAug 1, 2023
Revita+ ist eine wegweisende Partnerschaft zwischen dem Westdeutschen Diabetes- und Gesundheitszentrum (WDGZ) und Fractyl Health, die Revita mit Empfehlungen zu Änderungen des Lebensstils für Patienten mit Typ-2-Diabet...
Read MoreJun 26, 2023
Revita®, in conjunction with empagliflozin, provided a median HbA1c reduction of 1.6% and weight loss of 9.3% after 48 weeks while reducing insulin use by 44% in this inadequately controlled, insulin-dependent cohort R...
Read MoreJun 24, 2023
Revolutionary one-time pancreatic gene therapy resulted in up to 54% lower blood glucose and 20% lower total bodyweight than chronic semaglutide 10 nmol/kg/day in the db/db rodent model Proprietary Fractyl delivery tech...
Read MoreJun 13, 2023
LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, an organ-editing metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), announced today its participation in the upcomin...
Read MoreMay 18, 2023
Rejuva device & procedure reliably and successfully targets pancreas with Adeno Associated Virus (AAV), potentially enabling gene therapy to address pancreatic diseases for the first time Rejuva platform and genet...
Read MoreMay 9, 2023
LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it will be presenti...
Read MoreThe press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl Health disavows any obligation to update the information contained in such press releases after the date of their issuance.
Media Contact: Beth Brett, Corporate Communications
Bbrett@fractyl.com , +1 (720) 656-6544
In the News
Aug 17, 2023
A little intestinal fortitude sees Fractyl on track to reverse the root causes of T2D
Read MoreJun 30, 2023
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
Drug Delivery Business News
Read MoreJun 29, 2023
ADA meeting highlights new technologies for diabetes and updates for existing tech
Bio World
Read MoreJun 26, 2023
Studies back Fractyl Health diabetes reversal procedure, gene therapy
Mass Device
Read MoreApr 25, 2023
Fractyl Health initiates global registry for diabetes reversal treatment
Drug Delivery Business News
Read MoreMar 10, 2023
New and Developing Diabetes Technologies Offer ‘Sweet Relief’
Medical Product Outsourcing
Read MoreMar 7, 2023
Longevity investment bulletin: Mitobridge, Fractyl, Insilico and more
Longevity Technology
Read MoreFeb 13, 2023
Could an Intestinal Procedure Be the Future of Type 2 Diabetes Therapy?
diaTribe Learn
Read MoreJan 31, 2023
Fractyl Health ‘encouraged’ by results from diabetes reversal study
Mass Device
Read MoreDec 5, 2022
Data backs gene therapy delivery system for treating type 2 diabetes from Fractyl Health
Drug Delivery Business News
Read MoreOct 10, 2022
Fractyl Health Doubles Lab Space with 78K-SF Lease at GenLabs in Burlington
Connect CRE
Read MoreMay 21, 2021
How Fractyl is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections
Drug Delivery Business News
Read MoreApr 27, 2021
Fractyl gets FDA breakthrough nod for intestinal resurfacing in type 2 diabetes
BioWorld
Read MoreMar 22, 2021
Will Fractyl be Successful in Eliminating the Need for Daily Insulin?
MDDI Online
Read More